CD274 and ovarian cancer: Despite these results seen in Phase I, a Phase II study (KEYNOTE-100, NCT02674061), of pembrolizumab in advanced recurrent ovarian cancer demonstrated reduced benefit in the overall population but demonstrated higher response rates in PD-L1 high populations [106].